These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22724397)

  • 1. Biological perspectives: the role of glutamate in schizophrenia and its treatment.
    Steele D; Moore RL; Swan NA; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2012 Jul; 48(3):125-8. PubMed ID: 22724397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate as a therapeutic target in psychiatric disorders.
    Javitt DC
    Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
    Fell MJ; McKinzie DL; Monn JA; Svensson KA
    Neuropharmacology; 2012 Mar; 62(3):1473-83. PubMed ID: 21704048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antischizophrenic activity independent of dopamine D2 blockade.
    Kalkman HO
    Expert Opin Ther Targets; 2002 Oct; 6(5):571-82. PubMed ID: 12387681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glutamate synapses in schizophrenia.
    Field JR; Walker AG; Conn PJ
    Trends Mol Med; 2011 Dec; 17(12):689-98. PubMed ID: 21955406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
    Chaki S
    Eur J Pharmacol; 2010 Aug; 639(1-3):59-66. PubMed ID: 20371240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A biochemical theory of schizophrenia].
    Kornhuber HH; Kornhuber J; Kim JS; Kornhuber ME
    Nervenarzt; 1984 Nov; 55(11):602-6. PubMed ID: 6151120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
    Kanuma K; Aoki T; Shimazaki Y
    Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
    Heresco-Levy U
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
    Javitt DC
    Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [About the NMDA-system again].
    Neuropsychopharmacol Hung; 2011 Mar; 13(1):2-3. PubMed ID: 21667571
    [No Abstract]   [Full Text] [Related]  

  • 16. Glycine modulators in schizophrenia.
    Javitt DC
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1067-72. PubMed ID: 12186269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
    Chaki S; Yoshida S; Okuyama S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):207-13. PubMed ID: 21226317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders.
    WieroĊ„ska JM; Pilc A
    Pharmacol Ther; 2019 Jan; 193():75-82. PubMed ID: 30149102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.